Current Report Filing (8-k)
May 14 2019 - 5:21PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
__________________________________________________________________________________________________________________________
FORM 8-K
__________________________________________________________________________________________________________________________
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event
reported): May 14, 2019
__________________________________________________________________________________________________________________________
PHIO PHARMACEUTICALS
CORP.
(Exact name of registrant as specified
in its charter)
__________________________________________________________________________________________________________________________
Delaware
|
|
001-36304
|
|
45-3215903
|
(State or other jurisdiction of
incorporation or organization)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
257 Simarano Drive, Suite 101
Marlborough, Massachusetts 01752
(Address of Principal Executive Offices)
(Zip Code)
Registrant’s telephone number,
including area code: (508) 767-3861
__________________________________________________________________________________________________________________________
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(see General Instruction A.2. below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
☐
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act.
☐
|
Item 2.02
|
Results of Operations and Financial Condition.
|
On May 14, 2019, Phio Pharmaceuticals Corp.
reported its results of operations for the quarter ended March 31, 2019. A copy of the press released is furnished as Exhibit 99.1
to this Current Report on Form 8-K (the “Report”).
The information in this Item 2.02 and attached as
Exhibit 99.1 to this Report will not be treated as “filed” for the purposes of Section 18 of the Securities
Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that
section. This information will not be incorporated by reference into any filing under the Securities Act of 1933, as
amended, or into another filing under the Exchange Act, unless that filing expressly incorporates this information by
reference.
|
Item 9.01
|
Financial Statements and Exhibits.
|
|
99.1
|
Press Release dated May 14, 2019
|
* * *
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
PHIO PHARMACEUTICALS CORP.
|
|
|
Date: May 14, 2019
|
By:
/s/ Gerrit Dispersyn
|
|
Gerrit Dispersyn, Dr. Med. Sc.
|
|
President and Chief Executive Officer
|
Phio Pharmaceuticals (NASDAQ:PHIO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Phio Pharmaceuticals (NASDAQ:PHIO)
Historical Stock Chart
From Sep 2023 to Sep 2024